MX2017012507A - Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos. - Google Patents
Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos.Info
- Publication number
- MX2017012507A MX2017012507A MX2017012507A MX2017012507A MX2017012507A MX 2017012507 A MX2017012507 A MX 2017012507A MX 2017012507 A MX2017012507 A MX 2017012507A MX 2017012507 A MX2017012507 A MX 2017012507A MX 2017012507 A MX2017012507 A MX 2017012507A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrole derivatives
- methoxy pyrrole
- acceptable salts
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
- OTODBDQJLMYYKQ-UHFFFAOYSA-N 3-methoxy-1h-pyrrole Chemical class COC=1C=CNC=1 OTODBDQJLMYYKQ-UHFFFAOYSA-N 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 208000007882 Gastritis Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000000689 peptic esophagitis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente invención proporciona un derivado de 4-metoxi-pirrol o una sal farmacéuticamente aceptable del mismo, un método de preparación del mismo y una composición farmacéutica que contiene el mismo. Los derivados de 4-metoxi-pirrol o las sales farmacéuticamente aceptables de los mismos según la presente invención no sólo tienen excelente actividad inhibidora de la bomba de protones, actividad de inhibición del daño gástrico y efectos de potenciación de factores defensivos, sino que también tienen una excelente actividad de erradicación contra H. pylori. Por tanto, los derivados de 4-metoxi-pirrol o las sales farmacéuticamente aceptables de los mismos pueden usarse eficazmente para la prevención y el tratamiento de daño gastrointestinal debido a úlcera del tracto gastrointestinal, gastritis, esofagitis por reflujo o H. pylori. Además, los derivados de 4-metoxi-pirrol o las sales farmacéuticamente aceptables de los mismos tienen actividades inhibidoras contra GPCR y por tanto pueden usarse eficazmente para la prevención y el tratamiento de enfermedades mediadas por receptor 5-HT o mediadas por receptor muscarínico de acetilcolina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150058712 | 2015-04-27 | ||
| KR1020160013588A KR101613245B1 (ko) | 2015-04-27 | 2016-02-03 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| PCT/KR2016/004411 WO2016175555A2 (en) | 2015-04-27 | 2016-04-27 | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012507A true MX2017012507A (es) | 2018-01-30 |
Family
ID=55916928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012507A MX2017012507A (es) | 2015-04-27 | 2016-04-27 | Derivados de 4-metoxi-pirrol novedosos o sales de los mismos y composicion farmaceutica que comprende los mismos. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10100010B1 (es) |
| EP (1) | EP3197867B1 (es) |
| JP (1) | JP6244498B1 (es) |
| KR (2) | KR101613245B1 (es) |
| CN (1) | CN107001263B (es) |
| AU (1) | AU2016255308B2 (es) |
| CA (1) | CA2977750C (es) |
| CL (1) | CL2017002571A1 (es) |
| CO (1) | CO2017010539A2 (es) |
| DO (2) | DOP2017000230A (es) |
| EC (1) | ECSP17071036A (es) |
| ES (1) | ES2703709T3 (es) |
| HR (1) | HRP20182066T1 (es) |
| HU (1) | HUE042449T2 (es) |
| MA (1) | MA40887B1 (es) |
| MX (1) | MX2017012507A (es) |
| MY (1) | MY193257A (es) |
| NZ (1) | NZ734896A (es) |
| PE (1) | PE20180022A1 (es) |
| PH (1) | PH12017501755A1 (es) |
| PL (1) | PL3197867T3 (es) |
| PT (1) | PT3197867T (es) |
| RS (1) | RS58076B1 (es) |
| RU (1) | RU2663895C1 (es) |
| SA (1) | SA517390127B1 (es) |
| SG (1) | SG11201706877RA (es) |
| SI (1) | SI3197867T1 (es) |
| TN (1) | TN2017000424A1 (es) |
| WO (1) | WO2016175555A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| WO2017164575A1 (en) * | 2016-03-25 | 2017-09-28 | Daewoong Pharmaceutical Co.,Ltd. | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine |
| KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| KR102233456B1 (ko) * | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| WO2020060213A1 (ko) | 2018-09-19 | 2020-03-26 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| KR102126576B1 (ko) * | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
| CA3157981C (en) * | 2019-12-18 | 2024-03-26 | Daewoong Pharmaceutical Co., Ltd. | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| AU2021293694B2 (en) * | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| WO2022051979A1 (zh) * | 2020-09-10 | 2022-03-17 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| JP2024500406A (ja) | 2020-12-18 | 2024-01-09 | デウン ファーマシューティカル カンパニー リミテッド | １－（５－（２，４－ジフルオロフェニル）－１－（（３－フルオロフェニル）スルホニル）－４－メトキシ－１ｈ－ピロール－３－イル）－ｎ－メチルメタンアミンを含む新規な経口投与用製剤 |
| AU2022280595A1 (en) | 2021-05-26 | 2023-11-09 | Daewoong Pharmaceutical Co., Ltd. | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| BR112023024578A2 (pt) | 2021-05-26 | 2024-02-06 | Daewoong Pharmaceutical Co Ltd | formulação para injeção compreendendo o composto 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina ou um sal farmaceuticamente aceitável do mesmo, uma ciclodextrina e um agente isotonizante, bem como uso terapêutico do referido composto |
| KR102556500B1 (ko) | 2021-11-19 | 2023-07-19 | 하나제약 주식회사 | 피롤 유도체 또는 이의 약학적 또는 식품학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 위장 질환의 예방, 개선 또는 치료용 조성물 |
| WO2023113458A1 (en) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
| CN118541361A (zh) * | 2021-12-15 | 2024-08-23 | 日东制药株式会社 | 1-磺酰基吡咯衍生物的新型盐、其制备方法和包括其的药物组合物 |
| MX2024007309A (es) | 2021-12-15 | 2024-06-26 | Daewoong Pharmaceutical Co Ltd | Regimen de dosificacion para composicion de inyeccion de fexuprazan. |
| KR20230102353A (ko) | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
| WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
| TW202411215A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| WO2023229323A1 (ko) * | 2022-05-23 | 2023-11-30 | 일동제약(주) | 6-메톡시피리딘-3-일 유도체의 제조방법 |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
| CN115557876A (zh) * | 2022-10-26 | 2023-01-03 | 四川国康药业有限公司 | 一种用于治疗消化性溃疡的3-芳环基磺酰基-1-n-杂吡咯衍生物、其制备方法和用途 |
| KR20240127136A (ko) * | 2023-02-15 | 2024-08-22 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04004464A (es) | 2001-11-08 | 2004-08-11 | Upjohn Co | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. |
| US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| CN101006082B (zh) | 2004-08-23 | 2010-09-29 | 伊莱利利公司 | 组胺h3受体药剂、制备方法和治疗用途 |
| CA2579087C (en) | 2004-09-03 | 2012-05-01 | Yuhan Corporation | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof |
| EP2301625B1 (en) | 2004-09-30 | 2017-07-19 | F. Hoffmann-La Roche AG | Compositions and methods for treating cognitive disorders |
| CA2582777A1 (en) * | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| DK1919865T3 (da) * | 2005-08-30 | 2011-05-23 | Takeda Pharmaceutical | 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl-substituerede 1-h-pyrrolderivater som syresekretionsinhibitorer |
| DE102005041246A1 (de) | 2005-08-31 | 2007-03-08 | Basf Coatings Ag | Von Molybän- und Wolframverbindungen freie, Cäsiumverbindungen enthaltende, härtbare Gemische auf der Basis blockierter Polyisocyanate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| CN102321077A (zh) | 2005-12-19 | 2012-01-18 | 拉夸里亚创药株式会社 | 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途 |
| ES2336275T3 (es) | 2006-05-04 | 2010-04-09 | Solvay Pharmaceuticals B.V. | Agonistas muscarinicos para tratar trastornos del control de impulsos. |
| DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| CN104718189B (zh) * | 2012-11-19 | 2017-03-15 | 江苏豪森药业集团有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
| TW201446761A (zh) | 2013-03-15 | 2014-12-16 | Acadia Pharm Inc | 蕈毒鹼（ｍｕｓｃａｒｉｎｉｃ）激動劑 |
| ITBS20130175A1 (it) | 2013-11-22 | 2015-05-23 | Ind Saleri Italo Spa | Gruppo pompa di raffreddamento regolabile con girante regolabile |
| US10040780B2 (en) | 2014-03-03 | 2018-08-07 | The Regents Of The University Of California | Mcl-1 antagonists |
| CN104447191B (zh) | 2014-10-30 | 2016-03-23 | 绵阳达高特新材料有限公司 | 4-溴-1,2-二氢环丁烯并[α]萘化合物及其制备方法 |
| CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
-
2016
- 2016-02-03 KR KR1020160013588A patent/KR101613245B1/ko active IP Right Grant
- 2016-04-08 KR KR1020160043522A patent/KR101818704B1/ko active IP Right Grant
- 2016-04-27 MY MYPI2017703532A patent/MY193257A/en unknown
- 2016-04-27 JP JP2017531371A patent/JP6244498B1/ja active Active
- 2016-04-27 CA CA2977750A patent/CA2977750C/en active Active
- 2016-04-27 SG SG11201706877RA patent/SG11201706877RA/en unknown
- 2016-04-27 US US15/520,518 patent/US10100010B1/en active Active
- 2016-04-27 MX MX2017012507A patent/MX2017012507A/es active IP Right Grant
- 2016-04-27 WO PCT/KR2016/004411 patent/WO2016175555A2/en active Application Filing
- 2016-04-27 PE PE2017001632A patent/PE20180022A1/es unknown
- 2016-04-27 RU RU2017133866A patent/RU2663895C1/ru active
- 2016-04-27 PL PL16786741T patent/PL3197867T3/pl unknown
- 2016-04-27 RS RS20181555A patent/RS58076B1/sr unknown
- 2016-04-27 PT PT16786741T patent/PT3197867T/pt unknown
- 2016-04-27 NZ NZ734896A patent/NZ734896A/en unknown
- 2016-04-27 ES ES16786741T patent/ES2703709T3/es active Active
- 2016-04-27 TN TNP/2017/000424A patent/TN2017000424A1/en unknown
- 2016-04-27 AU AU2016255308A patent/AU2016255308B2/en active Active
- 2016-04-27 MA MA40887A patent/MA40887B1/fr unknown
- 2016-04-27 CN CN201680003652.8A patent/CN107001263B/zh active Active
- 2016-04-27 EP EP16786741.5A patent/EP3197867B1/en active Active
- 2016-04-27 HU HUE16786741A patent/HUE042449T2/hu unknown
- 2016-04-27 SI SI201630148T patent/SI3197867T1/sl unknown
-
2017
- 2017-09-25 PH PH12017501755A patent/PH12017501755A1/en unknown
- 2017-10-03 DO DO2017000230A patent/DOP2017000230A/es unknown
- 2017-10-10 SA SA517390127A patent/SA517390127B1/ar unknown
- 2017-10-11 CL CL2017002571A patent/CL2017002571A1/es unknown
- 2017-10-13 CO CONC2017/0010539A patent/CO2017010539A2/es unknown
- 2017-10-25 EC ECIEPI201771036A patent/ECSP17071036A/es unknown
-
2018
- 2018-12-06 HR HRP20182066TT patent/HRP20182066T1/hr unknown
-
2021
- 2021-10-18 DO DO2021000213A patent/DOP2021000213A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501755A1 (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
| EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| CN106536480A8 (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| WO2015200680A8 (en) | Prmt5 inhibitors and uses thereof | |
| MX2018009220A (es) | Nueva sal de adicion acida de 1-(5-(2,4-difluorfenil)-1-((3-fluorf enil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina. | |
| IN2014KN00948A (es) | ||
| UA118380C2 (uk) | Заміщені сполуки дигідроізохінолінону | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| NZ746825A (en) | Oxysterols and methods of use thereof | |
| SG11201900298RA (en) | Heterocyclic compound used as fgfr inhibitor | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| MX2019001781A (es) | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
| GEP20125526B (en) | Drug active in neuropathic pain | |
| WO2015199418A3 (ko) | 신규한 헤테로고리 화합물 | |
| MX2015012600A (es) | Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas. | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| WO2016122289A3 (ko) | 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물 | |
| WO2016069542A3 (en) | Lactone compounds and methods of making and using same | |
| WO2011102668A3 (ko) | 콜키친 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 | |
| MX365021B (es) | Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |